NASDAQ · INBS

Intelligent Bio Solutions Inc.

$1.75 -$0.06 (-3.31%) 1D After hours

Key Metrics

$4.33M
Market cap
P/E · TTM
$3.48M
Revenue · TTM
−$11.61M
Net income
EPS · TTM $-10.28
Dividend yield
Free cash flow
Beta · 1Y 1.38
EBITDA · TTM
Gross margin 53.1%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 24
    From its Jan 29 high, the share price fell 81%.

    Peak close $9.00 on Jan 29; trough close $1.75 on Jul 24. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -81%
  • Jul 23
    A material event was filed (Form 8-K).

    8-K - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)

    RECEIPT: SEC FORM 8-K, TIMESTAMPED
  • Jul 21
    A material event was filed (Form 8-K).

    8-K - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)

    RECEIPT: SEC FORM 8-K, TIMESTAMPED
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • May 13
    The stock moved +25.5% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 13
  • May 11
    The stock moved +33.1% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 11

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$4.33M
Enterprise value
Shares outstanding2.4M
52-wk range$0.64 – $24.90
Avg volume · 20D500.7K
Net cash
Book value / share$7.93
IndustrySurgical & Medical Instruments & Apparatus
ExchangeNASDAQ
About Intelligent Bio Solutions Inc.
IPO dateDec 23, 2020
Employees55

Intelligent Bio Solutions Inc is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S1.24
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross 53.1%
Operating -335.7%
Net -333.7%
FCF
ROE / ROIC -129.6% · —

Financial Health

Current ratio2.11
Quick ratio1.98
Debt / equity
Debt / EBITDA
Net cash
Working capital$5.14M

Cash Flow · TTM

Operating CF −$10.95M
Capex
Free cash flow
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

1 / 9
Weak fundamentals · 1 of 9 signals passing

Altman Z-Score

-8.2
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings